glp-1 agonist therapy Essentials New GLP-1 Guidelines for Type
Description
There are notable differences between the two
Survodutide : Phase 2 completed for obesity (Lancet 2024) and MASH (NEJM 2024)
Furthermore, ongoing monitoring allows for adjustments based on patient response
SemaKare digital support system provides injection training and tele-support
weekly) and route of administration (injectable vs
